31 October 2024
Futura
Medical plc
("Futura", "the Group" or the "Company")
Total
Voting Rights
Futura Medical plc (AIM: FUM),
the consumer healthcare company behind Eroxon®, that
specialises in the development and global commercialisation of
innovative and clinically proven sexual health products, announces
that for the purposes of the FCA's Disclosure and Transparency
Rules, the Company's total issued share capital at the date of this
announcement is 303,703,568 Ordinary Shares.
Since the Company currently holds no
shares in treasury, the total number of voting rights in the
Company is 303,703,568 and this figure may therefore be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change in their interest in, the share capital of the Company
under the FCA's Disclosure and Transparency Rules.
Contacts:
|
Futura Medical plc
|
James Barder
Chief Executive Officer
Angela Hildreth
Finance Director and COO
|
investor.relations@futuramedical.com
+44 (0)1483 685 670
www.futuramedical.com
|
|
Panmure Liberum
Nominated Adviser
and Broker
|
Emma Earl,
Will Goode, Mark Rogers (Corporate Finance)
Rupert Dearden (Corporate
Broking)
|
+44 (0)20 3100 2000
|
|
|
|
|
|
Stifel Nicolaus Europe Limited
Joint Broker
|
Alan Selby
Ben Maddison
|
+44 (0)207 710 7600
|
|
|
|
|
|
Alma
Strategic Communications
|
Rebecca Sanders-Hewett
Sam Modlin
Will Ellis Hancock
|
+44 (0)20 3405 0205
futura@almastrategic.com
|
|
|
|
|
Notes to Editors:
Futura Medical plc (AIM: FUM) is the
developer of innovative sexual health products, including lead
product Eroxon. Our core strength lies in our research, development
and commercialisation of topically delivered gel formulations in
sexual health products.
Eroxon, Futura's clinically proven
lead product, has been developed for the treatment of Erectile
Dysfunction ("ED"). The highly differentiated product, which is the
only topical gel treatment for ED available over the counter and
helps men get an erection in ten minutes, addresses significant
unmet needs in the ED market.
ED impacts 1 in 5 men globally across
all adult age brackets, with approximately half of all men over 40
experiencing ED and 25% of all new diagnoses being in men under
40.
Futura has distribution partners in
place in a number of major consumer markets including Haleon in the
US, the largest market for ED in the world, and Cooper Consumer
Health in Europe. Eroxon has been nominated for a number of
healthcare industry awards and has won two to-date.
